SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Feb. 17, 2004--Meditech Pharmaceuticals Inc. (OTC BB: MDCH - News) announced today that the results of the Cold Sore (HSV-1) clinical trials conducted at the Boston University Medical Center are being published today in the Journal of Medical Internet Research (www.jmir.org).
To prevent denial of publication for reasons of "pre-publication," and to preserve our rights under our pending patent application, the study results have been kept confidential pending publication.
Meditech is a drug development company focused on the development of human, veterinary and agricultural antimicrobial agents as well as its interest in a joint venture with Elan-Bio in their bio-terrorism scanner. Meditech was founded in 1982 as Medical Technology Corp. of America and went public via an IPO in 1983.
This press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results and events to differ materially. For a discussion of other risks that could cause actual results or events to differ materially from such forward-looking statements, see the discussion of ("Risks That Could Affect Our Financial Condition and Results of Operations") in Meditech's 10-KSB filing with the SEC for the year ended May 31, 2003. Meditech undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Meditech Pharmaceuticals Inc., Scottsdale Cindy Kern, 480-614-2874 Fax: 480-614-0560 email@example.com http://www.mdch.net
Source: Meditech Pharmaceuticals Inc.